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Abstract 
The endothelium plays a pivotal role in maintaining vascular health. Obesity is a global epidemic that has seen 
dramatic increases in both adult and pediatric populations. Obesity perturbs the integrity of normal endothelium, 
leading to endothelial dysfunction which predisposes the patient to cardiovascular diseases. MicroRNAs (miRNAs) are 
short, single‑stranded, non‑coding RNA molecules that play important roles in a variety of cellular processes such as 
differentiation, proliferation, apoptosis, and stress response; their alteration contributes to the development of many 
pathologies including obesity. Mediators of obesity‑induced endothelial dysfunction include altered endothelial nitric 
oxide synthase (eNOS), Sirtuin 1 (SIRT1), oxidative stress, autophagy machinery and endoplasmic reticulum (ER) stress. 
All of these factors have been shown to be either directly or indirectly caused by gene regulatory mechanisms of 
miRNAs. In this review, we aim to provide a comprehensive description of the therapeutic potential of miRNAs to treat 
obesity‑induced endothelial dysfunction. This may lead to the identification of new targets for interventions that may 
prevent or delay the development of obesity‑related cardiovascular disease.
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Background
Obesity is a major worldwide public health issue [1]. 
In the past decade, the incidence of obesity has rap-
idly risen to epidemic proportions [2, 3]. In the United 
States, obesity continues to be one of the leading public 
health crises. Almost a third of the American popula-
tion is affected by obesity (Body mass index (BMI) > 30), 
and 60% fall into the overweight category (BMI > 25) [4, 
5]. It is crucial to address and treat obesity because it is 
classified as a risk factor in the development of cardiovas-
cular disease [6]. Diverse mechanisms by which obesity 
promotes cardiovascular disease have been proposed, 
and most involve endothelial dysfunction [7]. Vascular 
function assessments in subjects with obesity have dem-
onstrated altered properties of endothelial function [8, 9]. 
Many studies have established that endothelial dysfunc-
tion can be considered as the first step in the progression 
of cardiovascular disease [10–13]. Thus, a better under-
standing of the mediators of obesity-induced endothelial 
dysfunction will help us to identify new targets for inter-
ventions that may prevent or postpone the development 
of obesity-related cardiovascular disease.
MicroRNAs (miRNAs) are noncoding small RNAs that 
play a central role in a wide range of biological cellular 
functions [14]. Altered microRNA expression has been 
reported in association with many different human dis-
eases such as cancer, neurodevelopmental, metabolic, 
and cardiovascular diseases [15, 16]. Dysregulation of 
microRNAs affects the status and functions of different 
tissues and organs, including the endothelial dysfunction 
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that leads to obesity-induced cardiovascular diseases. In 
this review, we will first begin by revising the biogenesis, 
regulation and mechanism of action of miRNAs. Then, 
we will illustrate the importance of miRNAs as modula-
tors of endothelial function, and we will address the role 
of miRNAs in obesity-induced endothelial dysfunction.
MicroRNAs
MiRNAs are small (18–25 nucleotides (nt)), single-
stranded and non-coding RNA molecules that play 
important roles in multiple cellular processes such as 
differentiation, proliferation, apoptosis, stress response. 
Their alteration contributes to the development of many 
pathologies including obesity [17]. After the discov-
ery of the first miRNA, lin-4, in Caenorhabditis elegans 
in 1993 [18], researchers have since demonstrated that 
these small molecules are an abundant class of RNAs 
in all prokaryotic and eukaryotic cells [19, 20]. To date, 
2654 human miRNAs have been uncovered [21] and each 
single miRNA can regulate the expression of several dif-
ferent genes. Additionally, different miRNAs can cooper-
atively regulate the expression of a target gene. This fact 
exposes the high complexity of the regulatory network 
constituted by the miRNAs and their targets [22]. In 
mammals, miRNAs can bind, either partially or totally, to 
the 3′UTR regions of a wide variety of mRNAs in order 
to prevent their translation into proteins or induce their 
degradation [20] (Fig. 1).
MiRNAs biogenesis, regulation, and mechanism of action
While most of the gene-encoding miRNAs are incor-
porated into the genome and are expressed using their 
own promoter, a minority are located within the introns 
and are transcribed as part of the annotated genes [20]. 
During miRNA biogenesis, the gene-encoding miRNA 
transcription is mediated mainly by RNA polymerase 
II (Pol II) and to a lesser extent by RNA polymerase III 
(Pol III), producing RNA precursors named pri-miRNAs. 
These pri-miRNAs are accessorized with their own CAP 
and poly-A tail, at 5′ and 3′ endpoints, respectively [23]. 
Every pri-miRNA contains a stem (~ 33  pb), a terminal 
loop, and a single-stranded RNA segment (ssRNA) [23, 
24]. The pri-miRNAs then enter the maturation process 
where two ribonuclease-mediated reactions are required 
[20]. The process begins in the nucleus, where it is medi-
ated by Drosha, a RNase type III protein; afterward, the 
process moves to the cytoplasm where it is mediated by 
Dicer, a type III endoribonuclease [25]. In the nucleus, 
Fig. 1 Summarized scheme of miRNAs biogenesis and mechanism of action: In the nucleus, Pol II and Pol III RNA polymerases transcribe the coding 
sequences of miRNAs. Drosha binds to DGCR8 cofactor to catalyze the formation of pre‑miRNA. Pre‑miRNA is then translocated by the exportins 
system from the nucleus to the cytoplasm, where it is then cleaved by the Dicer‑TRBP complex to form a 22nt‑dsRNA. Within the cytoplasm, the 
22nt‑dsRNA interacts with AGO proteins to form the RISC complex, while the passenger strand is degraded. The 22nt‑RNA guide chain constitutes 
a mature miRNA that guides the RISC complex towards the 3‑UTR regions of the mRNA targets. This interaction either represses their translation or 
induces their degradation. Pol: polymerase; Drosha: ribonuclease III double‑stranded RNA‑specific endoribonuclease; DGCR8: DiGeorge syndrome 
chromosomal region 8; Dicer: helicase with RNase motif; TRBP: TAR RNA binding protein; AGO: Argonaute protein; RISC: RNA‑induced silencing 
complex; UTR: untranslated region
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Drosha binds to Di George Syndrome Critical Region 
Gene 8 (DGCR8) cofactor to form a complex known as 
a microprocessor [25, 26]. The DGCR8 part of this com-
plex then binds to pri-miRNA’ s stem and loop struc-
ture, allowing Drosha to catalyze the breaking of the 
double strand of RNA in the stem. This cleavage induces 
the release of a fragment of 70 nt with hairpin structure 
called precursor miRNA (Pre-miRNA) [27, 28]. Follow-
ing this, Exportin-5 and its cofactor, Ras-related nuclear 
Guanine nucleotide-binding proteins (Ran-GTP) export 
the newly formed pre-miRNAs to the cytoplasm where 
the second reaction of the maturation process takes place 
[29]. In the cytoplasm, Dicer cleaves the pre-miRNAs 
near the terminal loop structure, creating a double-
stranded miRNA (dsRNA) fragment of approximately 22 
nt [30]. Dicer additionally interacts with TAR RNA-bind-
ing protein (TRBP), contributing to the formation of the 
RNA-Inducing Silencing Complex (RISC) [31–33]. The 
newly formed 22 nt- dsRNA binds to the protein Argo-
naute (Ago) to generate the effector complex, RISC. The 
guide RNA chain of 22 nt remains in the RISC complex 
as a mature miRNA, while the transient chain is degraded 
in some cases [29]. Next, the seed sequence of the mature 
miRNA facilitates specific recognition of the 3-UTR 
regions of the target mRNAs by guiding the RISC effec-
tor complex to recognize the target mRNA and nega-
tively signal its expression. When the complementarity of 
sequences between the seed sequence of the miRNA and 
the 3-UTR region of the target mRNA is imperfect, ribo-
somal access to the mRNA is blocked, thereby repressing 
translation. On the other hand, when the complementa-
rity is perfect, the target mRNA is degraded [30] (Fig. 1).
Obesity, microRNAs and endothelial dysfunction
The endothelium, a monolayer of endothelial cells (ECs) 
coating the vascular lumen, is the first point of contact 
between the blood components and the vascular wall 
[34–36]. Under physiological conditions, the endothe-
lium is able to respond to physical and chemical stimuli 
by releasing several different factors that play key roles in 
regulating cellular adhesion, thromboresistance, smooth 
muscle cell proliferation, inflammation, and vascular tone 
[37, 38]. Of particular note, the endothelium responds to 
changes in blood flow or chemical agents by releasing 
molecules that induce the vessel to relax or constrict [35]. 
Some of these molecules, such as nitric oxide (NO), pos-
sesses vasodilatory properties [37], while others, such as 
endothelin [39], are vasoconstrictors. By regulating vessel 
tone and diameter, this vasomotion is directly involved 
in balancing oxygen supply with the metabolic demands 
of tissues [40]. The imbalance between vasoconstric-
tor and vasodilatory markers is a notable feature of 
cardiovascular diseases and will lead to vascular endothe-
lial dysfunction [41].
Clinical studies have shown that patients with obe-
sity display lower levels of NO bioavailability, leading to 
impairment of endothelium-dependent vasodilation [42]. 
These studies have established that decreased expression 
of endothelial nitric oxide synthase (eNOS), the enzyme 
responsible for NO production in the endothelium, is the 
major cause for endothelial dysfunction in obesity [8].
Furthermore, evidence indicates that the enzyme 
NAD-dependent deacetylase sirtuin-1 (SIRT1), which 
deacetylates proteins that contribute to cellular regu-
lation during stress, plays a pivotal role in endothelial 
homeostasis by increasing eNOS gene expression [43]. 
Interestingly, SIRT1 has been found to be reduced during 
obesity, thereby leading to endothelial dysfunction [44].
Obesity has additionally been shown to induce several 
cellular stresses that impair endothelial function. These 
major stresses include oxidative stress [45], endoplas-
mic reticulum (ER) stress [46, 47], autophagy disruption 
[48], and inflammation [49]. All these stressors have been 
shown to decrease NO bioavailability during obesity and 
as a consequence, lead to endothelial dysfunction [49] 
(Fig. 2).
Recently, in  vitro and in  vivo studies have established 
that miRNAs are crucial for ECs gene expression, regu-
lation and function in various pathological conditions 
including obesity [17, 50, 51]. In this review, we will pro-
vide an overview of the miRNA role in controlling the 
key connecting mechanism between endothelial dysfunc-
tion and obesity.
Endothelial nitric oxide synthase and miRNAs
In the endothelium, NO is synthesized through the acti-
vation of eNOS [37]. Calcium  (Ca2+) entry into the ECs 
activates eNOS, which then transforms l-arginine into 
l-citrulline, leading to NO production. NO will diffuse 
from the ECs to the smooth muscle cells where it acti-
vates the soluble guanylate cyclase and increases the lev-
els of cyclic guanosine monophosphate (cGMP) thereby 
causing vasodilatation. A major contributing factor to 
decreased NO bioavailability is the downregulation of 
eNOS mRNA expression [37].
MiRNAs have been shown to play an important role in 
regulating eNOS [52]. Therefore, we can consider that a 
loss of eNOS RNA messenger during obesity [8, 53] may 
be due to a change in miRNA profile during obesity. In 
this section, we will discuss further the interplay between 
miRNAs and eNOS in the context of obesity-induced 
endothelial dysfunction (Fig. 3).
Recent evidences have established the important role 
of miR-24 in regulating eNOS in the vasculature [54–
57]. Interestingly, miR-24 is well known to be increased 
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during obesity in diverse tissues including abdominal 
adipose tissue [58], liver [59] and hypothalamus [60]. 
Although there are no published studies investigating 
the role of miR-24 in ECs during obesity, in vitro studies 
have demonstrated that miR-24 significantly inhibits ECs 
proliferation and eNOS gene expression [54]. It is well 
known that endothelial dysfunction underlies the rela-
tionship between obesity and atherosclerosis [61]. eNOS 
deficiency accelerates atherosclerotic lesion formation in 
mice [62]. Similarly, miR-24 exacerbates atherogenesis 
and promote atheromatous plaque formation [63]. These 
findings suggest that further exploration of obesity-
induced miR-24 upregulation may yield new therapeutic 
strategies for obesity-induced endothelial dysfunction.
MiR-155 has been described as an essential regula-
tor of eNOS expression and endothelial function [64], 
and its inhibition is suggested to be a useful approach 
for restoring endothelial function during the develop-
ment of cardiovascular diseases [64]. Interestingly, higher 
levels of miR-155 expression have been exhibited in 
adipose and kidney tissue from mice and patients with 
obesity [65, 66]. In addition, miR-155 deletion abolished 
high fat diet (HFD)-induced adipocyte hypertrophy and 
inflammation, [65] indicating a detrimental role of miR-
155 in obesity. ECs pretreated with Tumor Necrosis 
Factor (TNF)-α, known to be increased during obesity, 
displayed higher levels of miR-155 [67]. Moreover, TNF-α 
has been shown to play an important role in endothelial 
dysfunction during obesity [68] and metabolic diseases 
[69]. All together, these studies suggest a potential thera-
peutic for miR-155 inhibition in obesity-induced cardio-
vascular diseases.
Among the miRNAs that have been shown to play a 
direct role in regulating eNOS are miR-15b and miR-16 
[70]. Expressed in ECs, these miRNAs interact directly 
with eNOS by targeting its mRNA at 3UTR [70]. Inter-
estingly, these two miRNAs are known to be increased 
in obesity [71, 72]. Inhibition of miR-15b reduced 
hepatic insulin resistance in obesity [71], while inhi-
bition of miR-16 decreased inflammation [73]. Both 
insulin resistance and inflammation are frequently 
associated with endothelial dysfunction and have been 
proposed to play a major role in cardiovascular diseases 
[49, 74]. Although further studies are needed, these 
findings suggest that miR-15b and miR-16 inhibition 
in animal models or patients with obesity will protect 
Fig. 2 Obesity induces endothelial dysfunction. Obesity induces a decrease in NO bioavailability by: reducing eNOS activation and/or expression; 
negatively regulating SIRT1; and inducing cellular stresses including oxidative stress, ER stress and autophagy disruption. All of these effects lead to 
endothelial dysfunction. NO: Nitric Oxide; eNOS: endothelial Nitric Oxide Synthase; SIRT1: Sirtuin 1; ER: endoplasmic reticulum
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against eNOS mRNA degradation and can potentially 
prevent obesity-induced vascular dysfunction.
Another key player in vascular endothelial biology is 
miR-221/222, which is known to directly target eNOS 
[75]. Expression of this miRNA is upregulated in ECs 
during atherosclerosis and obesity [75]. In particular, 
it has been shown that miR-221/222 downregulates 
eNOS expression, leading to lower NO production 
in the vasculature during atherosclerosis [75]. Thus, 
inhibiting miR-221/222 could have clinical therapeutic 
effect in patients with obesity.
Finally, miR-765, the most abundant miRNAs 
detected in ECs [76], is known to bind directly to 
eNOS  mRNA, leading to the mRNA’s destabilization 
[76, 77]. Patients with coronary artery disease display 
high levels of circulatory miR-765, suggesting its role as 
a biomarker for coronary artery disease [78]. Although 
this study did not directly correlate miR-765 to obesity, 
a diversity of evidences has demonstrated that obesity 
is highly associated to coronary artery disease [79–81]. 
Therefore, the assessment of miR-765 changes in ECs 
during obesity would be an interesting step to consider 
in the pursuit of therapeutic approaches against obe-
sity-induced endothelial dysfunction (Table 1).
Other miRNAs have been shown to affect eNOS 
through indirect signaling pathways such as Protein 
kinase B (AKT) (miR-21,  miR-26, miR-181b,  miR-
221/222, and miR-486) [82, 83] and Caveolin1 (miR-132 
and miR-124) [84–86]. However, in this review, we have 
discussed only those miRNAs that directly affect eNOS.
Sirtuin 1 and miRNAs
Sirtuin 1 (SIRT 1) is a member of a class III histone dea-
cetylase family proteins (HDACs) dependent on nico-
tinamide adenine dinucleotide  (NAD+) [87]. SIRT1 
deacetylates histone proteins in addition to transcrip-
tion factors and cofactors involved in gene regulation 
[88]. SIRT1 is considered the major metabolic regulator 
because of its ability to regulate several factors involved 
in energy homeostasis [89, 90]. Recent evidence supports 
the idea that SIRT1, which is highly expressed in ECs, 
plays an important role in the regulation of endothelial 
function [91, 92]. In fact, SIRT1 is involved in regulat-
ing reactive oxygen species (ROS) production, increasing 
Fig. 3 Obesity, eNOS, miRNAs and endothelial function.  Ca2+ activates eNOS which then converts l‑Arginine to l‑Citrulline, producing NO as a 
byproduct. NO, synthetized through eNOS phosphorylation in the endothelium, will diffuse to the smooth muscle cells and increase the levels of 
cGMP, which then induce vasodilatation. During obesity, higher levels of miR‑24, miR‑155, miR‑15b, miR‑16, miR‑221/222 and miR‑765 are expressed 
and directly inhibit eNOS translation, thereby causing endothelial dysfunction. Other miRNAs have been shown to affect eNOS through indirect 
signaling pathways such as AKT (miR‑21, miR‑26, miR‑221/222, and miR‑486) and Caveolin1 (miR‑132 and miR‑124). eNOS: endothelial Nitric Oxide 
Synthase; NO: Nitric Oxide; cGMP: cyclic guanosine monophosphate; Cav1: Caveolin 1; AKT: Protein kinase B
Page 6 of 26Ait‑Aissa et al. Cardiovasc Diabetol          (2020) 19:136 
NO bioavailability, inhibiting vascular growth factors 
and reducing senescence modulators to maintain the 
endothelial homeostasis. During pathophysiological con-
ditions, such as obesity, SIRT1 expression is altered in 
the vasculature leading to endothelial dysfunction [92–
95]. Our recent data have demonstrated that SIRT1 is 
reduced in ECs from obese mice, while protecting SIRT1 
preserves endothelial function by protecting caveolin-1 
expression and reducing ER stress [91] (Fig. 4).
Our group has further demonstrated that miR-204 is 
an important factor that regulates vascular SIRT1 [91]. 
During obesity, miR-204 is highly expressed in ECs, 
leading to decreased levels of SIRT1 and endothelial 
dysfunction. Inhibition of miR-204 rescues impaired 
endothelial-dependent vasorelaxation and vascular 
expression of SIRT1 [91]. These findings indicate that 
SIRT-1 is a direct target of miR-204 and manipulat-
ing vascular miR-204 expression during obesity can 




Refs. Function Refs. Target Refs.
miR‑24 Up [58–60] Exacerbates atherogenesis and plaque formation [62, 63] eNOS [54–57]
miR‑155 Up [65, 66] Adipocytes hypertrophy and inflammation [65] eNOS [64]
miR‑15b Up [71, 72] Hepatic insulin resistance [71] eNOS [70]
miR‑16 Up [71, 72] Increases inflammation [73] eNOS [70]
miR‑221/222 Up [75] Increases atherosclerosis [75] eNOS [75]
miR‑765 Unknown – Coronary artery disease [78] eNOS [76, 77]
Fig. 4 Obesity, SIRT1, miRNAs and endothelial function. SIRT1 directly deacetylates eNOS, PGC‑1 α, p53, and FoxO1 leading to enhanced NO 
bioavailability and mitochondrial biogenesis as well as, decreased senescence, angiogenesis, apoptosis, and oxidative stress. All of these effects 
allow for the maintenance of endothelial homeostasis. Levels of miRNAs that directly target SIRT1 and thereby modulate endothelial function can 
be either increased (miR‑204, miR‑34a, miR‑132, miR‑217 and miR‑200c) or decreased (miR‑149) in obesity. SIRT1: Sirtuin 1; eNOS: endothelial Nitric 
Oxide Synthase; NO: Nitric Oxide; ROS: Reactive oxygen species; SOD2: Superoxide dismutase; P53: Tumor protein; FoxO: Forkhead box; PGC‑1 α: 
Peroxisome proliferator‑activated receptor gamma coactivator 1‑alpha
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potentially be a great therapeutic target against obesity-
induced endothelial dysfunction.
Obesity is also known to increase endothelial senes-
cence and as a consequence, leads to endothelial dys-
function [96, 97]. Several miRNAs have been shown to 
be involved in endothelial senescence, including miR-
217 and miR-34a [98, 99]. These two miRNAs share a 
similar function as negative regulators of  SIRT1 [98, 
100]. Other studies have shown that overexpression of 
miR-217 and miR-34a in ECs from young individuals 
decreased  SIRT1  expression and remarkably induced 
premature cell senescence [98, 99]. Interestingly, these 
two miRNAs are increased during obesity [100, 101]. 
From these findings, one could speculate that during 
obesity, these two upregulated miRNAs could influence 
the endothelial function through decreasing SIRT1 and 
inducing premature senescence pathways. Thus, further 
investigations of this pathway constitute a promising 
therapeutic strategy.
In addition, other studies have established miR-149 as 
an important player in preventing endothelial dysfunc-
tion [102]. MiR-149 stimulates the activity of SIRT1-
induced peroxisome proliferator-activated receptor γ 
coactivator 1 alpha (PGC1α) and mitochondrial bio-
genesis [103]. Upregulation of PGC-1α can prevent 
the development of, and even encourage regression of, 
atherosclerotic lesions during obesity [104]. HFD and 
obesity have been shown to significantly reduce the 
expression of miR-149, thereby lowering SIRT1 activ-
ity [103, 105]. These findings suggest that, by restoring 
SIRT1, vascular miR-149 overexpression may exert pro-
tective effects on obesity-induced endothelial damage.
Similarly, miR-132 has been described as a direct 
regulator of SIRT1 [106]. This miRNA has been shown 
to be increased during obesity and to induce inflamma-
tion in ECs via reduction of SIRT1 [106–108]. Inflam-
mation is tightly associated with vascular endothelial 
dysfunction in obese subjects [109]. Thus, regulating 
miR-132 level during obesity could have a beneficial 
effect on the endothelial function. All data are summa-
rized in Table 2.
Oxidative stress and miRNAs
Protein oxidation and ROS (free radicals) play a cru-
cial role in maintaining normal cell physiology [110]. 
The mitochondria are considered as the major source of 
ROS in most mammalian cells [111]. More specifically, 
the mitochondrial respiratory chain complexes I and III, 
located in the inner membrane of the mitochondria, gen-
erate the majority of superoxide anions (O2·) in the cell 
[111–114]. Nicotinamide-adenine dinucleotide phos-
phate (NADPH) oxidase, a cytoplasmic enzyme, is also 
known to contribute to ROS production, especially in 
the vasculature [115]. Under physiologic conditions and 
because of their high reactivity with other intracellular 
components, ROS generation is highly regulated by anti-
oxidant defense mechanisms that scavenge the detrimen-
tal actions of ROS [114]. The antioxidant defense systems 
include superoxide dismutases (SODs), glutathione per-
oxidase (GSHPx), catalases (CATs), and peroxiredoxins 
(PRDXs) [116]. For example, SODs induce the dismuta-
tion of O2· to form  H2O2 [116, 117]. At high proportions, 
 H2O2 possesses toxic properties, but its effects are coun-
teracted by GSHPx, CATs, and/or PRDXs [118]. Under 
pathophysiological conditions, an imbalance between 
the antioxidant system and the pro-oxidant species takes 
place and induces oxidative stress [119]. Studies have 
shown that oxidative stress by itself plays an important 
role in the pathogenesis of endothelial dysfunction dur-
ing obesity [49]. Because of their dual roles in vascular 
dysfunction and obesity, the following section will dis-
cuss the potential crosstalk between ROS and miRNAs 
in the context of obesity-induced endothelial dysfunction 
(Fig. 5).
MiRNAs are potent regulators of redox homeosta-
sis through antioxidant enzyme gene modulation [120, 
121]. Mitochondrial respiratory chain complex I func-
tion depends on the usage of iron/sulfur cluster assembly 
enzymes (ISCU) as transient electron carriers [122, 123]. 
Reduction in ISCU blocks the electrons from exiting 
complex I, causing electron leakage and increased levels 
of ROS [122]. Interestingly, miR-210 is known to impair 
mitochondrial respiratory activity by directly targeting 
ISCU 1 and 2 isoforms, which then leads to superoxide 




Refs. Function Refs. Target Refs.
miR‑204 Up [91] EC dysfunction [91] SIRT1 [91]
miR‑217 Up [101] Premature cell senescence [98] SIRT1 [98]
miR‑34a Up [100] Premature cell senescence [99] SIRT1 [100]
miR‑149 Down [103, 105] Regression of atherosclerotic lesions [104] SIRT1 [103]
miR‑132 Up [106–108] Macrophage infiltration in ECs [106–108] SIRT1 [106]
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anion production [124]. Additionally, recent evidence 
has shown that miR-210 induces ECs apoptosis during 
atherosclerosis [125] and is associated with cardiovas-
cular diseases [126–129]. Although these findings have 
established a strong correlation between miR-210 and 
mitochondrial ROS production during cardiovascular 
diseases, further investigation is needed to show its role 
in obesity-induced endothelial dysfunction.
As mentioned above, miRNAs can increase cellular 
ROS generation/levels by directly targeting antioxidant 
genes [120, 129]. For instance, miR-21, expressed in ECs 
[52] and reported to be increased in human subjects 
with obesity [130, 131], directly alters SOD expression in 
order to promote ROS production [132, 133]. Similarly, 
miR-551b has been shown to enhance ROS accumulation 
by directly inhibiting the gene expression of either CAT 
[134] or FOXO3a, the transcription factor that induces 
SOD and CAT transcription [135]. Both SOD and CAT 
play a crucial role in maintaining endothelial function 
[136–138]. Interestingly, increased levels of miR-551b 
lead to endothelial dysfunction in patients with coronary 
artery disease [139]. Higher expression levels of miR-
551b have been also reported in obesity [140]. Taken 
together, these findings suggest that inhibiting both miR-
21 and miR-551b could prevent oxidative stress and con-
sequently improve endothelial function in patients with 
obesity.
In diabetes, miR-200c is implicated in endothelial dys-
function, and its inhibition has been demonstrated to 
rescue endothelium-dependent vasodilation [141]. In 
subjects with obesity, miR-200c was found to circulate at 
higher levels [142, 143]. In addition, miR-200c negatively 
regulates redox proteins such as PRDX2, leading to accu-
mulation of ROS [144] and consequently to senescence 
Fig. 5 Obesity, oxidative stress, miRNAs and endothelial function. Superoxide anions (O2
·) are mainly produced by NOX2, NOX4 and mitochondria 
through electron transport chain complex I and III. Under physiological conditions, O2
· are highly regulated by antioxidant mechanism through 
SOD that detoxifies O2
· to hydrogen peroxide  (H2O2), which is then converted to water  (H2O) by catalase or glutathione peroxidase (GSHPx) and 
peroxiredoxins (PRDXs). Obesity interferes with the normal workings of this system. By decreasing miR‑448‑3p and miR‑19b, it increases NOX2 levels. 
At the same time, it decreases miR‑25 while increasing miR‑146a, which can cause up or downregulation of NOX4 levels respectively (NOX4 has 
dual effect). Additionally, obesity increases the levels of miR‑210 and miR‑29, both of which affect the mitochondrial respiratory chain. Moreover, 
obesity modulates the levels of miRNAs that regulate the antioxidant system (e.g. miR‑21 and miR‑17, both of which target SOD, with miR‑17 
additionally targeting GSHPx; and miR‑23b and miR‑200c, both of which target PRDXs). Altogether, the modulation of miRNA levels during obesity 
leads to excessive production of O2
· and consequently endothelial dysfunction. SOD: Superoxide dismutase; GSHPx: glutathione peroxidase; PRDXs: 
peroxiredoxins; NOX2: catalytic, membrane‑bound subunit of NADPH oxidase; NOX4: NADPH oxidase homolog
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and apoptosis in ECs [145]. Taken all together, these 
findings suggest that miR-200c plays a role in the patho-
physiological effects of obesity on endothelial function 
via oxidative stress. Additionally, miR-23b, which is 
expressed in ECs and plays an important role in vascu-
lar disorders [52, 146], has been shown to downregulate 
the antioxidant PRDX3 [147]. Furthermore, patients with 
cardiovascular disease risk display increased circulating 
levels of miR-23b [148]. These findings lead us to believe 
that miR-23b inhibition during obesity may induce ben-
eficial effects on endothelial function.
Major mitochondrial antioxidant enzymes, includ-
ing SOD and Gpx2, have been shown to be inhibited by 
miR-17 [149]. Furthermore, studies unveiled that miR-
17, upregulated through inflammatory processes [150], 
is involved in the pathogenesis of endothelial dysfunc-
tion in the context of obesity and diabetes [151, 152]. 
Although miR-17 expression has been correlated to obe-
sity-induced endothelial dysfunction, further pharmaco-
logical studies, in particular inhibitory experiments, are 
required to confirm its mechanisms of action.
MiR-29 isoforms have been described to affect the 
mitochondrial function leading to ROS production 
[153]. These isoforms are upregulated in animal mod-
els of metabolic disorder [154], induced endothelial cell 
dysfunction [155], and cellular senescence [156]. Because 
both endothelial dysfunction and senescence are pre-
sent during obesity [97], targeting miR-29 in the vascular 
endothelium during obesity may have a beneficial effect 
on endothelial function.
NADPH oxidase (NOX) 2 and 4 are isoforms of 
NADPH oxidase that are highly expressed in the vascu-
lature [115]. NOXs are known to be upregulated during 
obesity. This upregulation leads to excessive ROS pro-
duction and consequently to endothelial dysfunction 
[157]. Unlike NOX4, whose activity is induced constitu-
tively [158], the inducible NOX2 requires the interven-
tion of p47phox and p67phox as organizer and activator, 
respectively [159]. NOX2-derived ROS plays a major 
role in models of HFD-induced endothelial dysfunc-
tion [160]. In terms of relevant miR, miR-448 plays an 
important role in the regulation of NOX2-derived ROS 
production in the heart. In fact, silencing miR-448 sub-
stantially increases NOX2-derived ROS production and 
facilitates the development of cardiomyopathy [161]. In 
patients with obesity, miR-448 is expressed at low levels 
[162, 163]. While there are no direct studies of this miR 
in ECs, we anticipate that in a model of obesity-induced 
endothelial dysfunction, lower levels of miR-448 will 
induce NOX2-derived ROS production, which will then 
lead to impaired endothelial function.
In vitro studies have shown that miR-19b directly 
inhibits p47phox-induced ROS production [164]. 
Moreover, miR-19b has been reported to play a key role 
in the attenuation of inflammation-induced EC apopto-
sis [165]. In addition, decreased circulating levels of miR-
19b were observed in HFD-induced obese mice [166]. 
These findings imply that reduction of miR-19b in obesity 
may lead to increase in p47phox-induced ROS produc-
tion and endothelial dysfunction.
NOX4-derived ROS production has been implicated in 
endothelial dysfunction and inflammation during obesity 
[167, 168]. Evidence has shown that miR-25 is expressed 
in ECs [169]. Interestingly, in vitro inhibition of miR-25 
increases NOX4 expression and ROS levels, while its 
overexpression prevents NOX4-derived ROS production 
[170]. Rats under high cholesterol diet display lower miR-
25 expression, which is associated with increased NOX4 
expression levels [170]. While the relevance of these 
findings in the vasculature requires functional verifica-
tion, this study indicates that miR-25 may directly target 
NOX4 to induce ROS production in ECs during obesity.
Although several papers have reported the detrimental 
effects of NOX4-derived ROS production in the vascular 
system, other studies have demonstrated the beneficial 
effects of NOX4 in the vessel bed. In fact, NOX4 has been 
reported to induce eNOS upregulation and to inhibit vas-
cular inflammation during atherosclerosis [171, 172]. In 
this context, miR-146a has been shown to directly inhibit 
NOX4 expression, thereby causing endothelial inflamma-
tion [173]. Both animal models and patients with obesity 
express higher levels of miR-146a in adipose tissue [174]. 
Taken together, these studies point toward the impor-
tance of miR-146a in directly regulating the beneficial 
effects of NOX4 on the endothelium during obesity.
In summary, this section points toward the rising 
importance of studying the role of redox-sensitive micro-
RNAs in order to identify more effective biomarkers and 
develop better therapeutic targets for the plethora of oxi-
dative stress-related diseases, especially in the context 
of obesity-induced endothelial dysfunction. All data are 
summarized in Table 3.
Autophagy and miRNAs
Autophagy is an evolutionarily conserved mechanism 
that maintains cellular and nutrient homeostasis by 
degrading misfolded proteins and damaged organelles 
[175]. Dysregulation of autophagy is a major contributor 
to the pathogenesis of several chronic diseases includ-
ing obesity-induced cardiovascular dysfunction [176, 
177]. A number of recent studies have identified miRNAs 
that target autophagy-related proteins and that influ-
ence the autophagy flux. In this section, we will uncover 
the potential role of these miRNAs in the regulation of 
endothelial function in the context of obesity (Fig. 6).
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There are three forms of autophagy: macroautophagy, 
microautophagy, and chaperone-mediated autophagy 
[175]. In this review, we will focus only on macroau-
tophagy, which is the most important and well-studied 
in regard to obesity and endothelial function. Macroau-
tophagy is characterized by three main steps: initiation 
and vesicle nucleation, elongation and autophagosome 
formation, and fusion of the autophagosome with the 
lysosome and degradation. The whole process is called 
autophagy flux. The initiation phase is orchestrated by 
unc-51-like kinase 1 (ULK1) complex which consists of 
ULK1 itself, autophagy-related protein (ATG) 13, focal 
adhesion kinase family interacting protein of 200  kDa 
(FIP200), and ATG101. The ULK1 complex drives the 
formation of the phagophore, the initial autophago-
somal precursor membrane structure, through direct 
activation of vacuolar protein sorting 34 (VPS34) com-
plex. The VPS3A complex consists of the class III phos-
phatidylinositol 3-kinase (PIK3C3)/VPS34, BECLIN-1, 
VPS15 and ATG14-like. ULK1 activity is controlled 
by two nutrient-regulated protein kinases, 5′ adeno-
sine monophosphate-activated protein kinase (AMPK) 
and mammalian target of rapamycin (mTOR) complex 
1 (mTORC1). While AMPK upregulates autophagy in 
response to energy depletion by directly activating ULK1, 
mTORC1 keeps autophagy under control through direct 
inactivation of ULK1.
MiRNAs in the regulation of autophagy initiation
As important regulators of autophagy, mTOR and AMPK 
are regulated by miRNAs.
miR-155, miR-199a and miR-101 directly target mTOR 
in different cell types [178–182]. Interestingly, all three 
of these miRNAs have been found at increased levels 
during obesity and other metabolic diseases, and have 
been proven to have a detrimental effect on vascular 
and endothelial function [65, 183–188]. The relationship 
between mTOR and endothelial dysfunction is well doc-
umented [189]. In fact, a study has shown that chronic 
inhibition of the mTOR pathway in human aortic rings 
leads to a reduction in endothelium-mediated vasodila-
tion [190]. Moreover, obesity has been proven to reduce 
the activity of the mTOR pathway and lead to endothe-
lial dysfunction in vasculature of animal models of obe-
sity [191]. The reactivation of the mTOR pathway in these 
models improves microvascular endothelium-dependent 
vasodilation [191]. Altogether, these data provide a solid 
link between the miRNAs, obesity and endothelial dys-
function through mTOR regulation.
AMPK is also targeted by miRNAs, including miR-
148b and miR-451 [192, 193]. miR-148b is stimulated 
during obesity [194] and plays an important role in 
hyperglycemia-induced endothelial dysfunction [155]. 
miR-451 overexpression induces AMPK inhibition, 
which then leads to mTORC1 over-activation [195]. In 
addition, microarray analysis of the heart tissue of mice 
on HFD has shown that, by reducing AMPK, miR-451 
plays a role in the development of cardiac hypertrophy 
[193]. While this study uncovered the link between miR-
451 and AMPK during obesity, miR-451′s role in the vas-
cular endothelium and its contribution to the endothelial 
dysfunction in the context of obesity remains to be exam-
ined. The link between AMPK and endothelial dysfunc-
tion has been studied in HFD-induced animal models of 
obesity [196]. In this study conducted by Ma et al., HFD 
led to aortic AMPK downregulation and endothelial 
dysfunction [196]. Other studies have also shown that 
pharmacological activation of AMPK leads to markedly 





Refs. Function Refs. Target Refs.
miR‑210 Unknown – EC apoptosis and atherosclerosis [125] ISCU 1,2 [124]
miR‑21 Up [130, 131] Promotes ROS production [132, 133] SOD [132, 133]
miR‑551b Up [ [140] Enhances ROS accumulation [134, 135] CAT, SOD [134, 135]
miR‑200c Up [142, 143] EC apoptosis, ROS accumulation and senescence [144, 145] PRDX2 [144]
miR‑17 Up [151, 152] EC dysfunction [151, 152] SOD, Gpx2 [149]
miR‑23b Up [148] EC dysfunction [52, 146] PRDX3 [147]
miR‑29 Up [154] EC dysfunction, Cellular senescence [155, 156] ROS [153]
miR‑448 Down [162, 163] Attenuation of NOX2 induced‑ROS accumulation [161] NOX2 [161]
miR‑19b Down [166] Attenuation of inflammation‑induced EC apoptosis [165] p47phox [164]
miR‑25 Down [170] Prevent ROS production [170] NOX4 [170]
miR‑146a Up [174] EC inflammation [173] NOX4 [173]
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improved endothelial function [197]. Therefore, manipu-
lating miRNAs that target AMPK during obesity could 
be a relevant therapeutic tool to restore endothelial 
function.
A recent study has uncovered the protective role of 
ULK1 in obesity-induced cardiac damage [198]. Obe-
sity decreases ULK1 and leads to lipotoxicity in car-
diomyocytes and consequently heart dysfunction [198]. 
Despite the preventive role of ULK1 in the context of 
obesity-induced damage, the relation between ULK1 and 
endothelial dysfunction in obesity has not been stud-
ied. However, there is evidence that miR-199a inhibits 
ULK1 complex, which then causes vascular endothelial 
impairment and consequently hypertension [185]. Inter-
estingly, miR-199a is increased during obesity [182, 188], 
suggesting that manipulating this miRNA could restore 
endothelial function during obesity. Other studies have 
focused on miR-20a, miR-106b and miR-17-5p, three 
miRNAs proven to affect ULK1 complex [199–202]. 
Compared to healthy individuals, subjects with obesity 
display increased levels of miR-20a [143] which has been 
shown to regulate EC migration and angiogenesis, two 
important processes for endothelial function [203]. Simi-
larly, miR-106b has been found to be highly expressed 
during metabolic disorders, in which it induces mito-
chondrial dysfunction [204]; its knockdown counterpart 
Fig. 6 Obesity, autophagy flux, miRNAs and endothelial function. Autophagy flux consists of a series of steps including initiation, elongation, fusion 
of the autophagosome with the lysosome and degradation. Autophagy induction is controlled by mTOR and AMPK, which tightly regulate the 
ULK complex: ULK1, ATG13 and FIP200. By modulating miRNA levels, obesity regulates autophagy induction. During obesity, increased levels of 
miR‑155, miR‑199a‑5b and miR‑101 are expressed and all directly target mTOR. miR‑148b and miR‑451, also increased during obesity, target AMPK. 
miR‑199a, miR‑28a, miR‑106b and miR‑17‑5p target ULK1, while miR‑20a and miR‑20b target FIP200. Beclin1, which also plays an important role in 
autophagy initiation, is targeted by miR‑506‑3p, miR‑216a, miR‑129‑5p and miR‑376b. These four miRNAs are known to be increased during obesity. 
Autophagosome elongation involves ATG5, ATG7, ATG 12, ATG‑16L1, LC3 and p62. ATG 5 can be suppressed by miR‑181a and miR‑374a; ATG7 by 
miR‑210, miR‑188‑3p and miR‑137; ATG 12 by miR‑30d and miR‑630 and ATG 16‑L1 by miR‑20a and miR‑96. All these miRNAs are increased during 
obesity. LC3‑II is post‑transcriptionally controlled by miR‑204, which is known to be induced during obesity. P62 is controlled by miR‑17, miR‑20, 
miR‑93 and miR‑106, which are all also increased during obesity. The fusion and degradation step is controlled by UVRAG, LAMP‑1/2, RAB7, VAMP8 
and STX17. All of these membrane fusion factors are tightly regulated by miRNAs. UVRAG is suppressed by miR‑374, miR‑630, miR‑125, and miR‑351; 
Lamp1 is inhibited by miR‑23a and miR‑320a, while LAMP2 is inhibited by miR‑487‑5p; Rab7, VAMP8 and STX17 are regulated by miR‑30c, miR‑96, 
and miR‑124, respectively. All of these miRNAS are induced by obesity. In summary, the modulation that takes place in miRNA levels during obesity 
leads to autophagy flux disruption‑induced endothelial dysfunction. ULK1: unc‑51‑like kinase 1; FIP200: focal adhesion kinase family interacting 
protein of 200 kDa; mTOR: mammalian target of rapamycin; ATG: autophagy‑related protein; LC3: Microtubule‑associated protein 1A/1B‑light 
chain 3; p62: sequestrome 1; UVRAG: UV resistance‑associated gene; VAMP8: vesicle‑associated membrane protein; STX17: Syntaxin; LAMP: 
Lysosome‑associated membrane proteins; Rab7: Ras‑related protein
Page 12 of 26Ait‑Aissa et al. Cardiovasc Diabetol          (2020) 19:136 
decreases endothelial proliferation and prevents athero-
sclerosis [205]. Likewise, miR-17-5p expression differs 
significantly between patients with and without obesity 
[206]. Downregulation of this miRNA improves cardiac 
function after a myocardial infarction through attenua-
tion of EC apoptosis [207]. Altogether, these studies point 
toward the importance of the ULK1 in the cardiovascular 
system and more specifically endothelial function. There-
fore, monitoring the miRNAs that regulate the ULK1 
complex during obesity would have positive effects on 
the vascular bed.
Among the other players of autophagy initiation, miR-
20a and miR-20b have been shown to negatively regulate 
autophagy via targeting FIP200 [208]. Both miR-20a and 
miR-20b have been found at higher levels in patients with 
obesity [143, 209] and have been demonstrated to pro-
mote senescence in human microvascular ECs [210, 211]. 
Regulating these miRNAs, which regulate FIP200 during 
obesity, could have a beneficial effect on the endothelial 
function.
The reduction of Beclin 1 is associated with vascular 
ECs injury in hypertensive patients. In this study, Zhong 
et  al. showed that downregulating Beclin 1 expression 
in hypertensive patients via miR-506-3p upregulation, 
aggravates injury in vascular ECs [212]. Although the 
association between hypertension and obesity has been 
extensively studied and established [213–215], no study 
has linked miR-506-3p to obesity. Establishing this con-
nection could constitute an important advancement in 
obesity-induced vascular dysfunction therapy. Another 
player in the regulation of autophagy initiation is 
miR-216a. Mir-216a controls ox-LDL induced autophagy 
in ECs by regulating intracellular levels of Beclin1 and 
may have a therapeutic role in the pathogenesis of cardio-
vascular disorders and atherosclerosis [216]. MiR-129-5p, 
a known tumor suppressor [217], is induced during HFD 
and alters endothelial autophagy by directly binding to 
Beclin 1 [218]. Similarly, miR-376b, which is also found 
at high levels in subjects with obesity [219], targets Bec-
lin 1 and induce autophagy impairment in different cell 
types [220]. Interestingly, a study has uncovered the role 
of miR-376b in metabolic disease-induced EC dysfunc-
tion [155], suggesting that targeting this miRNA is a 
promising approach to regulate autophagy and endothe-
lial function during obesity. While the previous studies 
help establish a strong relationship between miRNAs and 
Beclin 1 in obesity, their relationship to obesity-induced 
endothelial dysfunction requires further exploration. All 
data are summarized in Table 4.
MiRNAs in the regulation of autophagy elongation
After vesicle nucleation, elongation of the phagophore’s 
membrane constitutes a fundamental step in the forma-
tion of a complete and functional autophagosome. This 
process involves ATG proteins (i.e. ATG 3, 4, 5, 7, 8, 10, 
12, and 16L) and the microtubule-associated protein 
1 light chain (LC3) [221]. The ATG system is required 
for the LC3 to conjugate to phosphotidylethanolamine 
(PE) phospholipids and to form LC3 II. LC3 II is impor-
tant for the expansion of the membrane, where it plays 
a crucial role in cargo recognition via its interaction to 





Refs. Function Refs. Target Refs.
miR‑155 Up [65] EC dysfunction [183] mTOR [178, 181]
miR‑199a Up [184, 188] EC dysfunction [185] mTOR, ULK1 [178, 180, 182, 185]
miR‑101 Up [186, 188] EC dysfunction [187] mTOR [178, 179]
miR‑451 Up [193] Cardiac hypertrophy [193] AMPK [193, 195]
miR‑148b Up [194] Hyperglycemia‑induced EC dysfunction [155] AMPK [192]
miR‑20a Up [143] Regulates EC migration, angiogenesis and 
senescence
[203, 211] ULK1, FIP200 [199, 208]
miR‑20b Up [209] Promotes EC senescence [210, 211] FIP200 [208]
miR‑106b Up [204] EC proliferation and atherosclerosis [205] ULK1 [199, 201]
miR‑17‑5p Up [206] ECs apoptosis and cardiac dysfunction [207] ULK1 [202]
miR‑506‑3p Unknown – Aggravates injury in vascular EC [212] Beclin 1 [ [212]
miR‑216a Unknown – Controls ox‑LDL induced autophagy [216] Beclin 1 [216]
miR‑129‑5p Up [218] Alters EC autophagy [218] Beclin 1 [218]
miR‑376b Up [219] Autophagy impairment, EC dysfunction [155, 220] Beclin 1 [220]
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sequestrome 1, also known as the ubiquitin-binding pro-
tein p62 [221].
Similar to the components of autophagy initiation, 
ATG proteins are regulated by multiple miRNAs. Beyond 
its major role in the autophagy elongation, ATG5 holds 
a pivotal part in the process cell survival [222]. As such, 
a variety of different miRNAs take part in its regulation. 
For instance, miR-181a is an active inhibitor of ATG5 
[223]. miR-181a is upregulated in human atherosclero-
sis plaques and involved in oxidative stress-induced EC 
dysfunction through by directly targeting autophagy 
machinery [224]. Moreover, it is found to be associated 
with the pathogenesis of obesity, [225] and its downregu-
lation has the potential to reverse these effects [226]. In 
a similar manner, miR-374a has been suggested to regu-
late ATG5 [227]. MiR-374a has been linked to metabolic 
disorder during obesity [228] and can promote heart 
dysfunction by negatively regulating vascular endothelial 
growth factor (VEGF) receptor-1 signaling [229].
MiR-30d, shown to directly target and suppress ATG12 
[230], is found at increased levels in subjects with obesity 
[58]. Although its implication in vascular function has 
not been assessed yet, existing data leads us to assume 
that downregulation of miR-30d in models with obesity, 
will induce a beneficial effect on endothelial function. 
Likewise, miR-630 suppresses autophagy by targeting 
ATG12 [230]. Interestingly, miRNA-630 has been desig-
nated as a putative key mediator of vascular function and 
cardiovascular disease risk in patients with obesity [231].
Similar to ATG12, ATG7 is also implicated in the devel-
opment of atherosclerosis [232]. This protein is shown to 
be negatively targeted by miR-210, miR-188-3p and miR-
137 [233–235]. MiR-210 is involved in ECs apoptosis 
during atherosclerosis [125] and is associated with car-
diovascular diseases [126–129]. Comparably, miR-188-3p 
upregulation results in the induction of atherosclerosis 
[236], a disease that has been widely associated with obe-
sity [61]. In regard to miR-137, which is also involved in 
obesity [237], studies have established that high glucose 
levels induce dysfunction of human ECs by upregulating 
miR-137 [238]. This suggests the involvement of miR-
137 in the pathogenesis of obesity-induced endothelial 
dysfunction.
ATG16L1 has been shown to be another target of miR-
NAs such as miR-20a [239] and miR-96 [240]. Interest-
ingly, both of these miRNAs are found to be upregulated 
during obesity [17, 241], and studies have demonstrated 
their implication in the functionality of the vascular sys-
tem [203, 242]. This indicates their potential involvement 
in the pathogenesis of obesity-induced vascular damage.
As important markers of autophagy process, LC3 and 
p62 are also regulated by miRNAs. To be specific, LC3 
is targeted by miR-204 [243]. Our group has previously 
shown that obesity is associated with increased levels of 
vascular miR-204, which lead to endothelial dysfunction 
[44]. From our findings, we believe that further exploring 
the mechanisms underlying obesity-induced endothelial 
damage with respect to miR-204 and autophagy could 
represent a novel strategy for obesity treatment and pre-
vention. On the other hand, p62 has been shown to be 
targeted by the miR-17/20/93/106 family of miRNAs 
[244]. Most of these family members are involved in 
endothelial dysfunction. In fact, when induced by VEGF, 
miR-17 triggers ECs to switch to an angiogenic pheno-
type which has been linked to atherosclerosis and obesity 
[245]. As discussed above, miR-20a, miR-20b and miR-
106 are all involved in the pathogenesis of obesity and 
endothelial dysfunction [17, 143, 192, 203, 205, 209–211]. 
Finally, miR-93, which plays an important role in adipo-
genesis [246], has been shown to regulate endothelial gly-
colysis and proliferation [247, 248] and to contribute to 
coronary atherosclerosis pathogenesis [239]. All data are 
summarized in Table 5.
MiRNAs in autophagy fusion and degradation regulation
Once the autophagosome has formed and matured, it 
fuses with a lysosome to form an autolysosome. The 
inner membrane of the former autophagosome and the 
engulfed cargo are then degraded by acid hydrolases 
[249]. Autophagosome–lysosome fusion machinery 
includes UV resistance-associated gene (UVRAG), Solu-
ble N-ethylmaleimide sensitive factor (NSF) Attachment 
Protein Receptor (SNARE) complexes, vesicle-associ-
ated membrane protein (VAMP) 8, Syntaxin (STX) 17, 
Lysosome-associated membrane proteins (LAMP) 1/2 
and RAB 7 [250]. Although poorly studied, a number 
of miRNAs have been reported to regulate the fusion of 
autophagosome and lysosome [251]. Studies have estab-
lished that lysosomal dysfunction occurs and is involved 
in the pathology of obesity [252]. In addition, lysosomal 
dysfunction has been proven to induce ECs apoptosis 
and senescence [253]. Therefore, regulating the late phase 
of autophagy during obesity could bring new insight into 
therapeutic approaches for vascular diseases.
UVRAG, an important player in the fusion process, 
is targeted by miR-374, miR-630, miR-125 and miR-351 
[227, 254]. The characteristics of both miR-374 and miR-
630 were discussed in the previous sections. miR-125 is 
implicated in the process of atherosclerosis development 
[255] and ECs senescence [256]. miR-351 is upregulated 
in the serum and ECs of atherosclerotic animal models 
and has been shown to attenuate ECs survival [257].
Lamp1, a primary marker of the lysosome fusion pro-
cess, is a target of both miR-23a [258] and miR-320a 
[259]. MiR-23a plays an important role in the develop-
ment of atherosclerotic plaques [260] and is a potential 
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marker for coronary artery disease [261]. miR-320a, on 
the other hand, has altered circulating levels in meta-
bolic diseases [262] and is considered a key regulator of 
atherogenesis [263].
Lamp2 is suppressed by miR-487-5p, [264] which has 
been found at higher levels in subjects with obesity [140]. 
Although no direct evidence has shown the implication 
of this miRNA in the vasculature, because Lamp2 is so 
crucially involved vascular function and integrity [265], 
we believe that we may gain some important insights 
by exploring this mechanism in the context of obesity-
induced endothelial dysfunction.
Implicated in atherosclerosis [266], miR-30c is an effi-
cient positive regulator of Rab7 [267]. Interestingly, both 
HFD and obesity downregulate miR-30c expression 
[268, 269] exacerbating the inflammatory process and 
cardiomyopathy. Although no evidence indicates that 
these processes would take place in the vascular bed in 
the context of obesity, data have demonstrated that res-
toration of autophagy flux through Rab7 in ECs reverses 
endothelial damages [270].
Finally, along the same lines, miR-96 has been pre-
dicted to bind to VAMP8 [271], and miR-124 to STX17 
[272]. Both miR-96 and miR-124 have been linked to 
metabolic disorders and EC impairment [241, 273–275].
In the above section, we have listed the miRNAs and 
dissected their regulatory roles in the autophagy flux 
pathway; however, the interplay between autophagy 
machinery and miRNAs is much more complex. DICER 
and the AGO2, enzymes that regulate miRNAs biogen-
esis [276], are direct targets of the autophagolysosomal 
degradation. This indicates that autophagy and miRNA 
interactions work both ways and controlling one way 
would lead to a disruption of other processes and alter 
other physiological cellular functions. Thus, it is impor-
tant to consider every single pathway that each miRNA is 
involved in, before exerting any potential manipulations 
in the context of obesity-induced vascular events. All 
data are summarized in Table 6.
Endoplasmic reticulum (ER) stress and miRNAs
The endoplasmic reticulum (ER) is the most impor-
tant subcellular membrane organelle. It plays a crucial 
role in protein synthesis and folding, as well as in the 
control of cellular calcium concentrations [277]. If the 
protein synthesis and folding process fails, proteins will 
accumulate inside the ER, automatically triggering a 
defense mechanism called unfolded protein response 
(UPR). UPR represses protein synthesis and increases 
ER chaperone content in a bid to restore normal ER 
function [278]. In mammalian cells, the UPR is acti-
vated by three specialized arms: protein kinase R-like 
ER kinase (PERK), inositol-requiring enzyme (IRE) 
1, and activating transcription factor (ATF) 6. Under 
normal conditions, 78  kDa-glucose-regulated protein/
immunoglobulin binding protein (GRP78/BIP), an ER 
chaperone, binds to and maintains the inactivity of 
IRE1α, PERK, and ATF-6. Under stressful conditions 
Table 5 MiRNA regulation during  obesity, their function in  the  cardiovascular system and  their potential targets 




Refs. Function Refs. Target Refs.
miR‑181a Up [225, 226] Oxidative stress‑induced EC dysfunction and atherosclerosis [224] ATG5 [223]
miR‑374a Up [228] Negatively regulates vascular endothelial growth factor recep‑
tor‑1 signaling
[229] ATG5 [227]
miR‑30d Up [58] Unknown – ATG12 [230]
miR‑630 Up [231] Suppresses autophagy [231] ATG12 [230]
miR‑210 Up [125] EC apoptosis and atherosclerosis [125] ATG7 [233]
miR‑188‑3p Unknown – Induction of atherosclerosis [236] ATG7 [234]
miR‑137 Up [237] EC dysfunction [238] ATG7 [235]
miR‑20a Up [17] EC dysfunction [203] ATG16L1 [239]
miR‑96 Up [241] EC dysfunction [242] ATG16L1 [240]
miR‑204 Up [44] EC dysfunction [ [44] LC3 [243]
miR‑17 Up [206] Triggers a switch of EC to an angiogenic phenotype [245] P62 [244]
miR‑93 Up [246] Regulates EC glycolysis and proliferation [239, 247, 248] P62 [244]
miR‑20a Up [17] Regulates EC migration, angiogenesis and senescence [203] P62 [244]
miR‑20b Up [209] Promotes EC senescence [210] P62 [244]
miR‑106 Up [204] EC proliferation and atherosclerosis [205] P62 [244]
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such as misfolded protein accumulation (also known as 
ER stress), GRP78/BIP dissociates from IRE1α, PERK, 
and ATF-6, activating them and l restructuring the 
UPR mechanism. Once activated, UPR alleviates pro-
tein load by halting transcription, slowing translation, 
and targeting misfolded proteins for degradation [279]. 
However, chronic ER stress can deleteriously affect cells 
and tissues by activating the inflammatory and apop-
totic pathways [280]. ER stress has been implicated 
in the pathogenesis of several obesity-related disor-
ders including diabetes, atherosclerosis, and endothe-
lial dysfunction [281–283]. Recent studies have linked 
microRNAs to the UPR pathway [284]. In this section, 
we will dissect the different pathways that link miRNAs 
and ER stress in regard to obesity-induced endothelial 
dysfunction (Fig. 7).
GRP78/BIP, a major ER chaperone protein, is critical 
for protein quality control and has been described as a 
master regulator of ER stress because of its anti-apop-
totic properties [285]. Recent evidence has indicated 
GRP78/BIP as a novel regulator of vascular endothe-
lial dysfunction [286, 287]. Several miRNAs, includ-
ing miR-30d, miR-181a, and miR-199a, directly target 
GRP78/BIP [288]. In several sections prior, we have dis-
cussed the potential involvement of each of these miR-
NAs in the pathogenesis of obesity-induced endothelial 
dysfunction [58, 182, 188, 224, 225].
MiR-204 affects ER-stress in human cells [289] by 
directly targeting and inhibiting PERK signaling and 
thereby causing ER-stress-induced cell death [290]. Our 
group has previously demonstrated that an increase in 
miR-204 expression in ECs during obesity is associated 
with increased ER stress, while inhibition of miR-204 
downregulates ER stress and restores endothelial func-
tion [91].
The transcriptional factor ATF 4, located downstream 
of PERK, has been implicated in microvascular endothe-
lial regulation pathways [291] and is suggested to have 
a role in the pathologic angiogenesis in atherosclerotic 
plaques [292]. This transcription factor is targeted and 
inhibited by miR-214 [293]. MiR-214 regulates endothe-
lial function and is altered in obesity [294, 295]. Another 
miR that is notable for its effects on ATF 4 is miR-663. 
Inhibition of miR-663 in aortic and venous ECs reduces 
ATF 4 levels [296], indicating that this miRNA may regu-
late expression of ATF 4. This microRNA has been linked 
to atherosclerosis [297] and demonstrated to regulate 
flow conditions, such as oscillatory shear in ECs, which is 
believed to contribute to atherosclerosis [298].
CCAAT-enhancer-binding protein homologous pro-
tein (CHOP), a proapoptotic transcription factor that is 
involved in the downstream cascade of ATF 4 [299], is a 
target of miR-211 [300]. While the circulatory levels of 
miR-211 are found to be increased in patients with ath-
erosclerosis [301], no evidence has linked miR-211 to 
endothelial function, despite the extensive number of 
studies establishing the interconnection between CHOP, 
ER stress, atherosclerosis and endothelial dysfunction 
[302]. We believe that further exploring the role of miR-
211 in the pathogenesis of obesity-induced endothelial 
dysfunction through ER stress pathways will uncover 
new mechanisms and offer a better understanding of the 
pathology.
A part of the UPR, IRE1α is regulated by miR-1291 
[303]. Although little is known about its involvement in 
the obesity-induced vascular damage pathogenesis, miR-
1291 has been shown to be increased in patients with 
myocardial infarction [304], a disease whose incidence is 
augmented by obesity [305] and is linked to endothelial 
dysfunction [306].
Table 6 MiRNA regulation during  obesity, their function in  the  cardiovascular system and  their potential targets 
in autophagy fusion and degradation machinery
miRNAs Up/downregulation 
(Obesity)
Refs. Function Refs. Target Refs.
miR‑374 Up [228] Deregulating vascular endothelial growth factor 
receptor‑1 signaling
[229] UVRAG [227]
miR‑630 Up [231] Suppresses autophagy [231] UVRAG [227]
miR‑125 Up [255, 256] EC senescence and atherosclerosis [255, 256] UVRAG [254]
miR‑351 Up [257] Attenuate EC survival [257] UVRAG [254]
miR‑23a Up [261] Promotes atherosclerotic plaque formation [260] Lamp1 [258]
miR‑320a Up [262] Regulates atherogenesis [263] Lamp1 [259]
miR‑487‑5p Up [140] Unknown – Lamp2 [264]
miR30c Down [268, 269] EC inflammation [268, 269] Rab7 [267]
miR‑96 Up [241] EC impairment [274] VAMP8 [271]
miR‑124 Up [273] EC apoptosis [275] STX17 [272]
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In the downstream signaling cascade, X-box bind-
ing protein 1 (XBP1) is a target of miR-214 and miR-30c 
[307, 308]. The implication of both miR-214 and miR-30c 
in the process of obesity-induced endothelial damage has 
been discussed earlier in this review.
Induction of the miR-23a-27a-24 cluster activates 
PERK and IRE1, which then leads to perturbation in 
intracellular calcium levels and mitochondrial function 
[309]. As mentioned above, miR-23a and miR-24 are 
associated to the pathogenesis of obesity and vascular 
endothelial damage [54, 55, 58, 63, 260, 261]. miR-27a is 
upregulated during obesity [310] and involved in athero-
sclerosis [311].
As the third arm of the UPR, ATF6 is not spared from 
miRNA regulation. MiR-221, miR-145 and miR-494 
are shown to be strong candidates in this matter [312]. 
Interestingly, miR-221 is elevated during obesity [313] 
and associated to EC dysfunction in the progression 
of atherosclerosis [314]. Both miR-145 and miR-494 
are related to obesity [315, 316] and atherosclerosis 
[317–319].
UPR by itself can exert a regulatory role on miRNAs; 
this aspect has been well described in the literature but 
not discussed here [284, 320]. Throughout this section, 
we have dissected the potential role that miRNAs may 
play on ER stress to exacerbate obesity-induced vascu-
lar damage. With these findings in mind, we believe that 
manipulation of each miRNA could offer a novel mecha-
nism and therapeutic approach to prevent endothelial 
dysfunction during obesity. All data are summarized in 
Table 7.
Challenges associated with clinical application
The miRNA research field has extensively grown in the 
last decade; however, the development of miRNA-based 
therapy remains very challenging. MiRNAs manipulation 
Fig. 7 Obesity, ER stress, miRNAs and endothelial function. Under ER stress, BIP will activate the three UPR sensor pathways that are initiated by 
PERK, ATF6, and IRE1. MicroRNAs involved in the UPR pathway and evidenced linkage to obesity and endothelial dysfunction are listed in this 
diagram. miR‑30d, miR‑181a, and miR‑199a‑5p have all been shown to directly target BIP. MiR‑204, miR‑23a, miR‑27a and miR‑24 directly target 
and inhibit PERK signaling, which then causes ER‑stress‑induced cell death. ATF4, located downstream of PERK, is directly inhibited by miR‑214 
and miR‑663. CHOP, which is regulated by ATF4, is suppressed by miR‑211. IRE1α and its downstream signaling XBP1 make up the second arm of 
the UPR; the former is targeted by miR‑1291, miR‑23a, miR‑27a and miR‑24, while the latter is targeted by miR‑214. Finally, in the third arm of UPR, 
miR‑221, miR‑145 and miR‑494 directly target ATF6. ER: endoplasmic reticulum; ATF6: Activating transcription factor 6; IRE1α inositol requiring 
enzyme 1 alpha; and PERK protein kinase‑like ER kinase; BIP: Binding Immunoglobulin Protein, also known as GRP78; UPR: unfolded protein 
response, ATF 4: Activating transcription factor 4; CHOP: CCAAT‑enhancer‑binding protein homologous protein; XBP1: X box binding protein 1; EI2 
α: Eukaryotic Initiation Factor 2 alpha
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mainly uses gain- and loss-of-function tools such as 
miRNA mimics, and antagonists and inhibitors, respec-
tively. The miRNA mimic technology is an innovative 
approach for overexpressing the mature sequence of the 
miRNA. Although miRNA mimics are advantageous 
in that they are easily synthesized and to behave in the 
same manner as their analog endogenous miRNA, they 
can lead to undesirable off-target effects because they 
non-selectively imitate the endogenous miRNA of even 
normal cells or tissues. The miRNAs antagonists, known 
as antagomirs, are 22–23nt RNA analogs that have a 
complementary sequence to the miRNA and silence 
the miRNA’s function. Despite the advantages of nucle-
ase resistance and their easy-delivery system, antago-
mirs often have off-target effects and induce unexpected 
side-effects. This occurs mostly because each miRNA 
can have different targets depending on the cell or tis-
sue type or because other miRNAs are acting on the 
same mRNA. Few studies have attempted to introduce 
these tools into clinical practice. One such study involves 
MRX34, a liposomal miR-34a mimic that is one of the 
first miRNA mimic to be put to clinical application; in 
2013, it was used as miRNA cancer therapy in patients 
with liver cancer and hematological malignancies [321]. 
Due to the adverse effects of this miRNA mimic, the 
study had to be discontinued before it reached phase II 
of the clinical trial. MRG-201, which mimics miR-29 and 
was being studied to determine its ability to limit the for-
mation of fibrous scar tissue, has seen more success up 
until this point [322]. It has successfully passed phase I of 
the clinical trial, and a phase II clinical trial is soon-to-be 
initiated, with the purpose of evaluating its efficacy in 
subjects with fibrotic diseases such as keloids formation.
Within the antagonist and inhibitor category, Mira-
virsen, a miR-122 inhibitor, has been established to effec-
tively combat hepatitis C viral infection [323]. Miravirsen 
is currently in phase II of the clinical trial and has shown 
beneficial outcomes without any notable adverse effects. 
With its ability to downregulate miR-122, this drug is 
currently a very promising combatant against hepatitis 
C. Likewise, MRG-106, a synthetic inhibitor of miR-155 
that plays an important role in cutaneous T cell lympho-
mas, has shown very promising results from phase I of 
its clinical trial. This has encouraged the investigation of 
MRG-106 to be continued and to include patients with 
additional hematological malignancies in which miR-155 
is known to be elevated and relevant.
Conclusion and future perspectives
The evidence that we have presented here in this review, 
helps to strengthen the concept that miRNAs constitute 
a good target for a based therapy tool against obesity-
induced endothelial damage. However, their multitude 
of targets and their interplay with different organs and 
subcellular organelles, makes them very non-specific 
and therefore prone to unwanted effects, should they be 
manipulated. Therefore, extensive bench side investiga-
tions are essential to harness the therapeutic potential of 
miRNAs while minimizing undesirable off-target effects. 
Investigations is most needed at the bench level. The 
achievement of this goal would constitute a breakthrough 
in current medicine.




Refs. Function Refs. Target Refs.
miR‑30d Up [58] Unknown – GRP78/BIP [288]
miR‑181a Up [225, 226] Oxidative stress‑induced EC dysfunction [224] GRP78/BIP [288]
miR‑199a Up [184, 188] EC dysfunction [185] GRP78/BIP [288]
miR‑204 Up [44] EC dysfunction [44] PERK [289, 290]
miR‑214 Up [294, 295] Regulates EC function [294, 295] ATF 4, XBP1 [293, 307]
miR‑663 Up [297] Regulates oscillatory shear in EC‑ atherosclerosis [297] ATF 4 [296]
miR‑211 Up [301] Promotes atherosclerosis [302] CHOP [300]
miR‑1291 Unknown – EC dysfunction [305, 306] UPR, IRE1α [303]
miR30c Down [268, 269] EC inflammation [268, 269] XBP1 [308]
miR‑24 Up [58–60] Exacerbates atherogenesis and plaque formation [62, 63] PERK&IRE1 [309]
miR‑23a Up [261] Promotes atherosclerotic plaque formation [260] PERK&IRE1 [309]
miR‑27a Up [310] Atherosclerosis formation [311] PERK&IRE1 [309]
miR‑221 Up [313] EC dysfunction [314] ATF6 [312]
miR‑145 Up [315] Promotes atherosclerosis [317] ATF6 [312]
miR‑494 Up [316] Promotes atherosclerosis [318, 319] ATF6 [312]
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ing transcription factor; GRP78/BIP: 78 kDa‑glucose‑regulated protein/immu‑
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